Login

Ray Blanco’s FDA Trader

Ray Blanco’s FDA Trader focuses on medical tech stocks with prices that move based on triggers generally unknown to the market.

It is designed to alert you to breakout moves could ultimately drive huge stock market gains...

Important: Flash Alert

One of our Ebola companies is now below our 45% stop loss point. All my research and sources tell me that this company’s Ebola medication is likely to be approved and used when Ebola becomes widespread. I still believe that a bigger, wider Ebola outbreak lies ahead. Because of the huge potential gains when that happens, I am going to retain this company in our portfolio…

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!


Ray Blanco’s FDA Trader

Ray Blanco’s FDA Trader focuses on medical tech stocks with prices that move based on triggers generally unknown to the market. It is designed to alert you to breakout moves in the medical markets that could ultimately drive huge stock market gains. It’s the single best way to connect the dots that link today’s dynamic, innovative medical market.

LoginGet Access

Paul Mampilly

Back when Paul Mampilly was growing up in India, nobody talked about the stock market. Yet as a kid, Paul read voraciously about the Great Crash of 1929 and found it fascinating.

When he turned 18, he came to the United States by himself. Since then, he’s had close to 25 years of investment...

View More By Paul Mampilly